![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Abgenix and Genentech Extend Technology Licensing Agreement
Abgenix and Genentech Extend Technology Licensing Agreement
March 14, 2005
Abgenix announced that Genentech has exercised its option to extend its technology licensing agreement with Abgenix for an additional three years. Under the extended agreement, Genentech will have access to Abgenix's proprietary antibody generation technology. As a condition of exercising the option, Genentech has purchased Abgenix common stock representing less than 1 percent of Abgenix's outstanding common stock through a private placement subject to future registration.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19366120&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct